Open AccessReal-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
Author(s) -
Devangna Bhatia,
Alexander Mehta,
Joanna DaCosta,
Oonagh Crothers,
James Talks
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s311816
Subject(s) - medicine , aflibercept , ranibizumab , choroidal neovascularization , macular degeneration , ophthalmology , dioptre , retrospective cohort study , visual acuity , cohort , bevacizumab , diabetic retinopathy , surgery , diabetes mellitus , chemotherapy , endocrinology
Evaluation of real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the primary treatment of choroidal neovascularization (CNV) secondary to pathological myopia.